Dana-Farber Cancer Institute, Boston, MA, USA.
Curr Hematol Malig Rep. 2019 Feb;14(1):11-21. doi: 10.1007/s11899-019-0493-y.
Lymphomas represent clinically and molecularly heterogeneous diseases with variable presentations, treatment algorithms, and outcomes. As treatment options continue to expand, more sophisticated prognostic and predictive biomarkers are needed to guide personalized treatment approaches.
Liquid biopsies, in which the sequencing of circulating tumor DNA (ctDNA) in peripheral blood serves as a surrogate for a tumor biopsy, are now being studied across cancer subtypes, including in lymphoid malignancies. Recent studies have demonstrated the potential of these techniques to improve prognostication and guide individualized treatment strategies, providing a significant advance in the field of precision medicine. In this review, we describe the sequencing platforms currently available for analysis of ctDNA in lymphoma and their potential applications in clinical practice, which seem poised to refine treatment paradigms across lymphoma subtypes.
淋巴瘤是一种临床表现和分子特征具有异质性的疾病，其治疗方案、结局也各不相同。随着治疗方案的不断扩展，需要更复杂的预后和预测生物标志物来指导个体化治疗方法。
液体活检，即通过外周血循环肿瘤 DNA（ctDNA）测序来替代肿瘤活检，目前正在包括淋巴恶性肿瘤在内的各种癌症亚型中进行研究。最近的研究表明，这些技术有可能改善预后并指导个体化治疗策略，这是精准医学领域的一项重大进展。在这篇综述中，我们描述了目前可用于淋巴瘤 ctDNA 分析的测序平台及其在临床实践中的潜在应用，这些应用似乎有望完善各种淋巴瘤亚型的治疗模式。
